Clinical Value of Serum Neurofilaments in Neurodegenerative Diseases

Investigating axonal damage through blood-based biomarkers has emerged as a major priority in clinical neurology. Specifically, serum neurofilaments represent structural cytoskeletal proteins released into the cerebrospinal fluid and bloodstream following neuronal injury or axonal degeneration. Although researchers have extensively characterized serum neurofilament light chain (sNfL), systematic evidence regarding serum neurofilament heavy chain (sNfH) has remained scarce across varied neurodegenerative cohorts. A rigorous German multicenter investigation recently addressed this knowledge gap by assessing both biomarkers across amyotrophic lateral sclerosis (ALS) and diverse dementia syndromes. The investigators evaluated 630 individuals from the German Frontotemporal Lobar Degeneration Consortium and an independent single-center validation cohort. Consequently, their findings deliver clear comparative benchmarks for clinicians evaluating motor and cognitive syndromes. Axonal breakdown occurs across multiple neurological disorders, yet the degree of protein release varies considerably. Therefore, validating accessible blood markers offers immense potential for routine outpatient assessment and prognostic stratification. Clinicians often encounter substantial diagnostic ambiguity during the initial stages of motor neuron disorders and dementias. Accordingly, measuring circulating neurofilament proteins offers a minimally invasive method to substantiate active neuroaxonal injury.

Diagnostic Performance in Amyotrophic Lateral Sclerosis and Mimics

Differentiating amyotrophic lateral sclerosis from benign or treatable neuromuscular mimics poses a persistent diagnostic hurdle. In this multicenter study, both sNfH and sNfL levels increased substantially in patients with ALS compared to healthy controls and disease mimics. However, sNfL exhibited superior diagnostic discrimination over sNfH when classifying active motor neuron disease. Specifically, sNfL achieved an area under the curve between 0.94 and 0.95, whereas sNfH yielded an area under the curve between 0.87 and 0.88. Furthermore, calculating the sNfH to sNfL ratio failed to improve overall discriminative precision over sNfL alone. Therefore, sNfL remains the more robust frontline parameter for confirming rapid motor neurodegeneration. Muscle disorders, benign fasciculations, and cervical radiculopathies frequently mimic early presentation of ALS. Because peripheral nerve mimics do not cause massive central axonal breakdown, circulating biomarkers remain relatively low in those conditions. Consequently, quantitative blood testing substantially shortens diagnostic delay. Early diagnostic certainty allows timely initiation of neuroprotective therapies and supportive multidisciplinary interventions. In addition, these blood biomarkers provide objective objective confirmation when electromyographic or clinical signs remain ambiguous.

Comparative Analysis Across Diverse Dementia Subtypes

The investigators also quantified serum neurofilaments across 289 patients presenting with various dementia phenotypes. Both sNfH and sNfL were significantly elevated across dementia cohorts compared to healthy control participants. Nevertheless, individual dementia subtypes exhibited remarkably divergent biomarker profiles. For example, sNfL concentrations were markedly higher in behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and Creutzfeldt-Jakob disease than in Alzheimer's disease. In contrast, sNfH concentrations remained comparable among Alzheimer's disease, primary progressive aphasia, and frontotemporal dementia cohorts. Thus, sNfL demonstrates distinct sensitivity to frontotemporal degeneration and rapid prion-mediated destruction. Frontotemporal spectrum disorders frequently involve accelerated subcortical and cortical axonal disintegration compared to classic amyloid-driven pathologies. Consequently, sNfL captures this intense axonal injury with superior granularity. Meanwhile, the limited variability of sNfH across dementia syndromes restricts its clinical utility in differential cognitive evaluation. Therefore, clinicians must select specific neurofilament assays judiciously when deciphering atypical presentations of cognitive impairment.

Prognostic Utility and Cognitive Decline Tracking

Beyond initial differential diagnosis, clinicians require reliable markers to predict patient trajectory and disease progression. Importantly, the German cohort study demonstrated that baseline sNfL correlated significantly with cognitive impairment at presentation. Furthermore, longitudinal assessments confirmed that elevated sNfL reliably predicted the rate of subsequent cognitive decline in Alzheimer's disease and frontotemporal dementia. In stark contrast, sNfH demonstrated no significant correlation with baseline cognitive deficits or subsequent rate of clinical decline. Consequently, sNfL functions as a valuable dynamic readout of ongoing neuroaxonal destruction and impending clinical deterioration. Because cognitive trajectories vary considerably among patients, baseline prognostic stratification aids in therapeutic counseling and clinical management. Serial measurement of sNfL could help clinicians identify rapid progressors who require intensified supportive care. Moreover, this differential predictive capability underscores fundamental biological distinctions between light and heavy neurofilament dynamics. Light chains appear more readily released and cleared into the vascular compartment, reflecting real-time neuroaxonal injury. Therefore, sNfL represents an ideal candidate for longitudinal monitoring in both routine care and clinical therapeutic trials.

Clinical Implications for Practice and Future Diagnostics

The integration of circulating neurofilament measurements represents a substantial advancement for outpatient neurology and geriatric practice. Obtaining blood samples causes minimal patient discomfort compared to invasive lumbar punctures, facilitating repeat testing. However, physicians must interpret elevated levels within the comprehensive clinical context rather than as isolated determinants. While elevated serum neurofilaments confirm active axonal damage, they do not pinpoint an exclusive molecular etiology. For instance, elevated concentrations occur in vascular insults, traumatic injuries, and inflammatory demyelination alongside degenerative disorders. Therefore, clinicians must combine biomarker testing with detailed clinical evaluations, electromyography, and high-resolution neuroimaging. In resource-conscious healthcare settings, selecting the most informative biomarker is paramount. Because sNfL consistently outperforms sNfH across diagnostic and prognostic domains, laboratories should prioritize validated sNfL immunoassays. Standardizing assay cutoffs across different analytical platforms will represent the final critical step before widespread implementation. Ultimately, blood biomarkers provide accessible, objective evidence that enhances diagnostic confidence and refines patient communication.

Frequently Asked Questions

What differentiates sNfL and sNfH in neurodegenerative diagnostics?

Both proteins indicate axonal damage, but sNfL demonstrates higher diagnostic sensitivity and discriminative accuracy than sNfH across motoneuron diseases and dementias. Furthermore, sNfL correlates closely with baseline cognitive impairment and predicts subsequent clinical decline, whereas sNfH lacks comparable prognostic utility in dementia monitoring.

Can serum neurofilaments reliably differentiate ALS from mimic syndromes?

Yes, circulating neurofilaments are significantly higher in ALS than in neuromuscular mimic conditions. Specifically, sNfL achieves excellent diagnostic accuracy with an area under the curve exceeding 0.94. This test provides objective evidence of rapid central axonal degeneration, helping clinicians distinguish ALS from mimics promptly.

How do serum neurofilaments assist in monitoring dementia progression?

Serum NfL tracks active neuroaxonal loss across dementia subtypes, rising particularly high in frontotemporal lobar degeneration and Creutzfeldt-Jakob disease. Elevated baseline sNfL levels correlate with accelerated future cognitive decline in Alzheimer's disease and frontotemporal dementia, providing valuable prognostic guidance during long-term patient follow-up.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Barba L et al. Serum neurofilaments for motoneuron and dementia diseases: a German multicenter cohort study. J Neurol. 2026 Jun 02. doi: 10.1007/s00415-026-13878-y. PMID: 42230361.


2. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light and heavy chains for the diagnosis and prognosis of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2019;90(8):870-881.


3. Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS: a systematic review and diagnostic meta-analysis. Lancet Neurol. 2017;16(8):600-612.